Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions

Official Title: “Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal® 1 mg Tablets Administered as a 1 x 1 mg Tablets in Subjects Under Fed Conditions”

The objective of this study was to compare the rate and extent of absorption of risperidone 1 mg tablets (test) versus Risperdal® (reference) administered as a 1 x 1 mg tablets under fed conditions.

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Intervention(s) in this Clinical Trial

• Drug: Risperidone
  • 1 mg Tablet
• Drug: Risperidone
  • 1 mg Tablet

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
  • Risperidone 1 mg Tablet
• Active Comparator: 2
  • Risperdal® 1 mg Tablet

Primary Measures

• Bioequivalence based on Cmax and AUC
  • Time Frame: 2 weeks
    Safety Issue?: No

Inclusion Criteria

• Subjects will be females and/or males, non-smokers, 18 years of age and older.
• Subjects should read, sign and date an Informed Consent Form prior to any study procedure.
• Female Subjects will be post-menopausal or surgically sterilezed.
• Post-menopausal status is defined as absence of menses for the past 12 months,
• Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at least 6 months ago.

Exclusion Criteria

Subjects to whom any of the following applies will be excluded from the study:

• Clinically significant illnesses within 4 weeks of the administration of study medication.
• Clinically significant surgery within 4 weeks prior to the administration of the study medication.
• Any history or presence of significant Neurological, hepatic, renal, endocrine, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
• Any clinically significant abnormality found during medical screening.
• Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.
• Abnormal laboratory tests judged clinically significant.
• Subjects who do not tolerate venipuncture.
• Positive urine drug screen at screening.
• Subjects who use tobacco in any form will not be eligible to participate in this study. Three months abstinence before screening is required.
• Positive testing for hepatitis B, hepatitis C or HIV at screening.
• ECG abnormalities (clinically significant) (PR interval greater than 225 msec or QTc segment greater than 450 msec) or vital sign abnormalities (systolic blood pressure lower than 100 or over 160 mmHg, or diastolic blood pressure lower than 60 or over 96; or heart rate less than 60 bpm) at screening.
• Subjects with BMI ≥30.0.
• History of seizures or other predisposing factors.
• History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day (1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
• History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana, pot) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
• History of cardiac disease or family history of cardiac disease.
• Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical subinvestigator, contraindicates the subject's participation in this study.
• History of allergic reactions to risperidone.
• Use of any drugs known to induce or inhibit hepatic drug metabolism, use of an investigational drug or participation on an investigation study within 30 days prior to the administration of the study medication.
• Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption.
• Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (500 mL) within 56 days prior to administration of the study medication.
• Positive alcohol breath test at screening.

Additional exclusion criteria for female subjects only:

• o Positive urine pregnancy test at screening (performed on all females).

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Investigator: Teva Pharmaceuticals USA Industry

Overall Clinical Trial Officials and Contacts

Benoit Girard, MD Principal Investigator Anapharm  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00829894

Study ID Number: 01173

ClinicalTrials.gov Identifier: NCT00829894

Health Authority: United States: Institutional Review Board